BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24010873)

  • 1. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database.
    Dakin H
    Health Qual Life Outcomes; 2013 Sep; 11():151. PubMed ID: 24010873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.
    Dakin H; Abel L; Burns R; Yang Y
    Health Qual Life Outcomes; 2018 Feb; 16(1):31. PubMed ID: 29433510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
    Liu T; Li S; Wang M; Sun Q; Chen G
    Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
    Khan KA; Petrou S; Rivero-Arias O; Walters SJ; Boyle SE
    Pharmacoeconomics; 2014 Jul; 32(7):693-706. PubMed ID: 24715604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample.
    Le QA; Doctor JN
    Med Care; 2011 May; 49(5):451-60. PubMed ID: 21422961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores.
    Gu NY; Bell C; Botteman MF; Ji X; Carter JA; van Hout B
    Patient; 2012; 5(3):185-97. PubMed ID: 22765255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping analysis to estimate EQ-5D utility values using the COPD assessment test in Korea.
    Lim J; Choi SE; Bae E; Kang D; Lim EA; Shin GS
    Health Qual Life Outcomes; 2019 Jun; 17(1):97. PubMed ID: 31170982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score.
    Dakin H; Gray A; Murray D
    Qual Life Res; 2013 Apr; 22(3):683-94. PubMed ID: 22555470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.
    Versteegh MM; Leunis A; Luime JJ; Boggild M; Uyl-de Groot CA; Stolk EA
    Med Decis Making; 2012; 32(4):554-68. PubMed ID: 22114301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
    Madan J; Khan KA; Petrou S; Lamb SE
    Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic mapping of the health status measure SF-12 onto the health utility measure EQ-5D using the US-population-based scoring models.
    Le QA
    Qual Life Res; 2014 Mar; 23(2):459-66. PubMed ID: 24026631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence on the relationship between PROMIS-29 and EQ-5D: a literature review.
    Pan T; Mulhern B; Viney R; Norman R; Tran-Duy A; Hanmer J; Devlin N
    Qual Life Res; 2022 Jan; 31(1):79-89. PubMed ID: 34181154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.